Skip to main content
. 2019 Jan 18;10(4):409–416. doi: 10.1136/flgastro-2018-101054

Figure 4.

Figure 4

Recommended algorithm for managing the transition from ustekinumab induction treatment to maintenance dosing. IV, intravenous; SC, subcutaneous.